HomeToday’s HighlightsAmgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Amgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Today’s Highlights April 10, 2019 Amgen and UDB Granted FDA Approval of Evenity™ Amgen (AMGN) and UCB Pharmaceuticals (This content is for paid subscribers. Please click here to subscribe or here to log in. Today’s Highlights Amgen (AMGN), UCB Pharmaceuticals (UCB) April 10, 2019 Tweet Pin It Other Articles BioArctic and Novartis Sign a Collaboration and License Agreement Using BrainTransporter™ August 27, 2025 0 Precigen Announces Full FDA Approval of PAPZIMEOS, the Only Currently Approved Treatment for Adults with Recurrent Respiratory Papillomatosis August 15, 2025 0 Approval of BRINSUPRI™ for the Treatment of Non-Cystic Fibrosis Bronchiectasis August 13, 2025 0 How Alnylam Pharmaceuticals Made Our Day Today and More July 31, 2025 0